Supplementary Table S2 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses

Supplementary Table S2 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses

<p>Supplemental Table S2 - Differential expression analysis of genes in leukemic or immune cells treated with sEV</p>

Kaydedildi:

Detaylı Bibliyografya
Yazar:	Ernesto Gargiulo (15134961) (author)
Diğer Yazarlar:	Elodie Viry (15134964) (author), Pablo Elías Morande (15134967) (author), Anne Largeot (15134970) (author), Susanne Gonder (15134973) (author), Feng Xian (15134976) (author), Nikolaos Ioannou (15134979) (author), Mohaned Benzarti (15134982) (author), Felix Bruno Kleine Borgmann (15134985) (author), Michel Mittelbronn (15134988) (author), Gunnar Dittmar (15134991) (author), Petr V. Nazarov (15134994) (author), Johannes Meiser (15134997) (author), Basile Stamatopoulos (15135000) (author), Alan G. Ramsay (15021857) (author), Etienne Moussay (15135003) (author), Jérôme Paggetti (15135006) (author)
Baskı/Yayın Bilgisi:	2025
Konular:	Cancer Tumor Biology Immuno-oncology Methods and Technology Hematological Cancers Leukemias Lymphomas Immunology T cell exhaustion Tumor resistance to immune response Preclinical Models Animal models of cancer Tumor Microenvironment Immune cells and the microenvironment
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller

Figure 1 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
Yazar:: Ernesto Gargiulo (15134961)
Baskı/Yayın Bilgisi: (2025)

Figure 2 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
Yazar:: Ernesto Gargiulo (15134961)
Baskı/Yayın Bilgisi: (2025)

Figure 3 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
Yazar:: Ernesto Gargiulo (15134961)
Baskı/Yayın Bilgisi: (2025)

Figure 4 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
Yazar:: Ernesto Gargiulo (15134961)
Baskı/Yayın Bilgisi: (2025)

Figure 5 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
Yazar:: Ernesto Gargiulo (15134961)
Baskı/Yayın Bilgisi: (2025)

Figure 6 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
Yazar:: Ernesto Gargiulo (15134961)
Baskı/Yayın Bilgisi: (2025)

Figure 7 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
Yazar:: Ernesto Gargiulo (15134961)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S1 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
Yazar:: Ernesto Gargiulo (15134961)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S3 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
Yazar:: Ernesto Gargiulo (15134961)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S4 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
Yazar:: Ernesto Gargiulo (15134961)
Baskı/Yayın Bilgisi: (2025)

Table S1 from HDACi-dependent Microenvironmental Normalization Overcomes Tumor Burden–induced T-cell Exhaustion
Yazar:: Andrew Nguyen (17142197)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure S1 from Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model
Yazar:: Shih-Shih Chen (15314296)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure S2 from Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model
Yazar:: Shih-Shih Chen (15314296)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure S3 from Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model
Yazar:: Shih-Shih Chen (15314296)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure S4 from Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model
Yazar:: Shih-Shih Chen (15314296)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure S5 from Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model
Yazar:: Shih-Shih Chen (15314296)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure S6 from Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model
Yazar:: Shih-Shih Chen (15314296)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S1 from Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model
Yazar:: Shih-Shih Chen (15314296)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table from CDK2 Inhibition Enhances Antitumor Immunity by Increasing IFN Response to Endogenous Retroviruses
Yazar:: Yu Chen (1234761)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table from CDK2 Inhibition Enhances Antitumor Immunity by Increasing IFN Response to Endogenous Retroviruses
Yazar:: Yu Chen (1234761)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table from CDK2 Inhibition Enhances Antitumor Immunity by Increasing IFN Response to Endogenous Retroviruses
Yazar:: Yu Chen (1234761)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table from CDK2 Inhibition Enhances Antitumor Immunity by Increasing IFN Response to Endogenous Retroviruses
Yazar:: Yu Chen (1234761)
Baskı/Yayın Bilgisi: (2025)

Suppl video 1 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
Yazar:: Andrew O. Yam (15293045)
Baskı/Yayın Bilgisi: (2025)

Suppl video 2 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
Yazar:: Andrew O. Yam (15293045)
Baskı/Yayın Bilgisi: (2025)

Suppl video 3 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
Yazar:: Andrew O. Yam (15293045)
Baskı/Yayın Bilgisi: (2025)

Suppl video 4 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
Yazar:: Andrew O. Yam (15293045)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table 1 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy
Yazar:: Andrew O. Yam (15293045)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S1 from CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer
Yazar:: Erika Y. Faraoni (14844897)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S3 from CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer
Yazar:: Erika Y. Faraoni (14844897)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S4 from CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer
Yazar:: Erika Y. Faraoni (14844897)
Baskı/Yayın Bilgisi: (2025)

Table S1 from Elevated Mast Cell Abundance Is Associated with Enrichment of CCR2<sup>+</sup> Cytotoxic T Cells and Favorable Prognosis in Lung Adenocarcinoma
Yazar:: Fanfan Fan (16799646)
Baskı/Yayın Bilgisi: (2025)

Table S2 from Elevated Mast Cell Abundance Is Associated with Enrichment of CCR2<sup>+</sup> Cytotoxic T Cells and Favorable Prognosis in Lung Adenocarcinoma
Yazar:: Fanfan Fan (16799646)
Baskı/Yayın Bilgisi: (2025)

Table S3 from Elevated Mast Cell Abundance Is Associated with Enrichment of CCR2<sup>+</sup> Cytotoxic T Cells and Favorable Prognosis in Lung Adenocarcinoma
Yazar:: Fanfan Fan (16799646)
Baskı/Yayın Bilgisi: (2025)

Table S4 from Elevated Mast Cell Abundance Is Associated with Enrichment of CCR2<sup>+</sup> Cytotoxic T Cells and Favorable Prognosis in Lung Adenocarcinoma
Yazar:: Fanfan Fan (16799646)
Baskı/Yayın Bilgisi: (2025)

Table S5 from Elevated Mast Cell Abundance Is Associated with Enrichment of CCR2<sup>+</sup> Cytotoxic T Cells and Favorable Prognosis in Lung Adenocarcinoma
Yazar:: Fanfan Fan (16799646)
Baskı/Yayın Bilgisi: (2025)

Table S6 from Elevated Mast Cell Abundance Is Associated with Enrichment of CCR2<sup>+</sup> Cytotoxic T Cells and Favorable Prognosis in Lung Adenocarcinoma
Yazar:: Fanfan Fan (16799646)
Baskı/Yayın Bilgisi: (2025)

Table S7 from Elevated Mast Cell Abundance Is Associated with Enrichment of CCR2<sup>+</sup> Cytotoxic T Cells and Favorable Prognosis in Lung Adenocarcinoma
Yazar:: Fanfan Fan (16799646)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data from PP2Ac Deficiency Enhances Tumor Immunogenicity by Activating STING–Type I Interferon Signaling in Glioblastoma
Yazar:: Isha Mondal (16721699)
Baskı/Yayın Bilgisi: (2025)

Figure S1 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
Yazar:: Dahihm Kim (16546203)
Baskı/Yayın Bilgisi: (2025)

Figure S2 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
Yazar:: Dahihm Kim (16546203)
Baskı/Yayın Bilgisi: (2025)

Cannot write session to /tmp/vufind_sessions/sess_sr3ufvntebuucdab8lv8qk4ng8